Redhill Biopharma Ltd., of Tel Aviv, Israel, reported final results from a phase I study of Yeliva (ABC294640), an oral sphingosine kinase-2 selective inhibitor, in patients with advanced solid tumors, which met its primary and secondary endpoints, demonstrating that the drug is well-tolerated and can be safely administered to cancer patients at doses that provide circulating drug levels that are predicted to have therapeutic activity. Read More

Alexza Pharmaceuticals Inc., of Mountain View, Calif., said Nasdaq will delist its common stock, which was suspended on June 17 and has not traded since. Read More

Kitov Pharmaceuticals Holdings Ltd., of Tel Aviv, Israel, said it closed its public offering of about 2.4 million class A units, with each unit consisting of one American depositary share (ADS) and a warrant to purchase one ADS, as well as about 1.2 million class B units, with each consisting of a nonlisted, pre-funded warrant to purchase one ADS and a listed warrant. Read More

LONDON – The first disclosure on June 30 of payments to health care professionals – intended to bolster pharma's claim to effective self-regulation – came just a week after one of the most egregious case of noncompliance with industry codes concluded and Astellas UK was booted out of the Association of the British Pharmaceutical Industry (ABPI) for an unprecedented 12 months. Read More

It doesn't matter whether a biosimilar sponsor dances the steps choreographed in the Biologics Price Competition and Innovation Act (BPCIA), the Federal Circuit ruled Tuesday. It still cannot serve the reference biologic maker with the required 180-day notice of commercial marketing until after the FDA licenses the biosimilar. Read More

SHANGHAI – Singapore-headquartered Aslan Pharmaceuticals Pte Ltd. is deepening its ties to Taiwan. The oncology-focused biopharma has been growing its operational presence in Taiwan over the last three years, and is now making moves to go public there in 2017. In preparation, Aslan took on $23 million in series D financing from a group of local and global investors. Read More

HONG KONG – A novel vaccine-based cancer treatment strategy, which can stimulate both an innate and an adaptive immune response, has been developed by scientists at the RIKEN Center for Integrative Medical Sciences (IMS) in Yokohama, Japan. That finding may ultimately result in more successful cancer treatments. Read More

A fully human antibody targeting interleukin (IL)-8 that wound its way through Medarex Inc. and Genmab A/S has found a new home at Bristol-Myers Squibb Co. (BMS) through the acquisition of Cormorant Pharmaceuticals AB. Read More

DUBLIN – Shares in Tigenix NV gained 23 percent Tuesday on news of a sizeable ex-U.S. deal with Takeda Pharmaceutical Co. Ltd. for its allogeneic cell therapy for Crohn's disease, Cx601, which is currently undergoing regulatory review in Europe. Read More

In the first quarter of 2016, private U.S. biopharmas tracked by BioWorld Snapshots raised about $380 million less than the same quarter in 2015, but the year-over-year decline was easy to shrug off because the first quarter of 2015 contained a monster $450 million series C round by Moderna Therapeutics Inc. Read More